LAUSR

Introduction The Carillon device was studied in a blinded randomized trial (REDUCE FMR) and demonstrated improvements in regurgitant volume (RV) and LV dimensions at one year compared to a sham control group. It is not clear what are the characteristics of better responders to this therapy, especially if sicker pts will respond. Methods Data from REDUCE FMR (included pts with EF's Results Results are summarized in Table 1.RV responders had lower EF's, similar LVEDV and higher RV's at baseline as compared to non-responders. LVEDV responders had lower EF's, larger LVEDV and more RV than LVEDV non-responders. Pts with afib were more likely to be a responder when the parameter was remodeling, but less likely to be a responder with regards to improvement in MR. Non-ischemics did better using either definition of responders. Continuous variable values are mean ±standard deviation* p Conclusions The Carillon device seems to have a greater impact in pts with worse EF's and more RV at baseline, representing a higher risk population. Although the use of Carillon may be clinically important in pts with lesser degrees of MR (catching them earlier in the disease), greater relative changes may be observed in sicker pt populations.